Background
==========

The field of addiction treatment lacks a universally accepted and unambiguously defined clinical definition of recovery. Although a single disciplinary group such as physicians may agree upon a definition, there is no such agreement among the broader field of treatment professionals, addiction researchers, program evaluators, and policymakers. Indeed, there is no comprehensive consensus of what a definition of \"recovery\" is even among those individuals who are themselves in recovery from substance use disorders \[[@B1],[@B2]\].

There have been many efforts to define recovery from substance use disorders. Perhaps the most often used criteria for remission from substance use disorders by treatment professionals are those from the *Diagnostic and Statistical Manual of Mental Disorders*(*DSM*) \[[@B3]\]. An example of such a criterion is the sum of all years in which a diagnosis of alcohol use disorder was not present. However, this criterion indicates a remission from a clinical diagnosis, rather than a multidimensional perspective on recovery.

Perhaps the most comprehensive efforts to define \"recovery\" were those offered by leading investigators as part of a special issue on \"recovery\" published by the *Journal of Substance Abuse Treatment*(October 2007). Methodological approaches to developing a definition of recovery included a consensus panel, literature reviews, surveys of the general public and addiction treatment professionals, and opinions from persons themselves in \"recovery\".

The Betty Ford Consensus Panel \[[@B4]\] defined \"recovery\" as consisting of three parts: sobriety, personal health, and citizenship. Sobriety refers to abstinence from alcohol and all other non-prescribed drugs; personal health refers to improved quality of health; and citizenship refers to living with regard and respect for others. This conceptualization has come under criticism for several reasons, including the use of the construct of citizenship as a measure of chemical dependency recovery. The objection is that no other chronic illness is measured for recovery status on the construct of citizenship \[[@B5]\]. The Betty Ford panel proposed measuring recovery using the World Health Organization Quality of Life instrument. However, this approach has been critiqued on the ground that a measure developed for a general population may not be valid for the specific population of people in recovery \[[@B5]\]. Arndt & Taylor \[[@B5]\] view the Betty Ford conceptualization as an initial step in defining \"recovery,\" rather than the pinnacle of a definition.

White \[[@B6]\] defined \"recovery\" as the experience (a process and sustained status) through which individuals, families and communities impacted by severe alcoholism and other drug problems utilize internal and external resources to voluntarily resolve these problems, heal the wounds inflicted by alcohol and other drug-related problems, and develop a healthy, meaningful and productive life. White \[[@B7]\] subsequently proposed outcome measures for these areas including measures of substance use, living environment, physical and emotional health, family relationships, citizenship, and quality of life.

Laudet \[[@B1]\] cites a survey of members of the public regarding their view of recovery (Peter D. Hart Research Associates, 2004). This survey indicated that 62% reported that \"in recovery from addiction to alcohol or other drugs, the one addicted is trying to stop using\". Only 22% of respondents reported that \"the one in recovery is free from the disease of addiction and no longer uses alcohol or illicit drugs\". Further, 80% of respondents expressed that total abstinence was their \"recovery\" goal and over 80% reported that \"recovery\" is a process and not a finite achievement. Apart from the public\'s perceptions, Laudet \[[@B1]\] also conducted a review of articles on recovery and concluded that most researchers operationally define recovery in terms of substance use and more often as abstinence status. Some of the terms used interchangeably were *remission, resolution, abstinence, and recovery*. In addition, words to represent the act of changing the substance using behaviors were *quit, overcome, and recover*. In these contexts, \"recovery\" is defined as \"overcoming both physical and psychological dependence to psychoactive drugs while making a commitment to society.\" This description implies domains of recovery that encompass drug abstinence, personal wellbeing, and re-integration into society.

Galanter \[[@B8]\] suggested a model of \"recovery\" from addiction that is attuned with the spiritual framework supported by Alcoholics Anonymous. This aspect of recovery is based on the substance-using individuals\' own perspectives. These experiences are not observable; rather, they are self-reported through the persons\' interpretations. This is an important domain of \"recovery\" and is reminiscent of the spiritual orientation of Alcoholics Anonymous.

Finally, McLellan, Chalk, & Bartlett \[[@B9]\] present \"recovery\" in terms of outcomes, performance, and quality. Calls for accountability within the addiction treatment field have inspired these authors to build a set of treatment quality, performance and outcome indicators. They suggest that outcomes of any treatment are the changes in clients\' symptoms, behaviors, and functioning that can be attributed to the treatment. Because clients present with multiple problems, outcome evaluations of chemical dependency treatment have measured more than one outcome variable. Outcome measures are generally grouped together by the domain of functioning that they represent. When clients experience abstinence or a substantial reduction in use of drugs/alcohol as well as improvement in functioning in other domains (e.g., family, social, education, financial, etc.) this can be called \"recovery.\" The three variables that are most frequently presented as \"recovery\" domains are substance use, employment/self-support, and criminal activity. The Substance Abuse and Mental Health Services Administration \[[@B10]\] measures substance abuse \"recovery\" by adjoining physical health, mental health, family and social relations, stability in housing, perception of care, access, and retention domains. According to SAMSHA, improvements in three of the seven functional domains plus abstinence are considered indicative of \"recovery\".

As can be seen from the above, the definition and very concept of recovery is unclear, although a convergence of ideas is beginning to emerge. It might be fundamental to consider the foregoing efforts, which represent collective federal agency/consensus panel/empirical definitions of \"recovery\" as a starting point meant to be reviewed, revised, expanded upon, revisited, and updated. Therefore, the purpose of this article is to move toward an abstinence-based model of recovery by using existing models and developing upon them. This article is theoretical in nature and does not present quantitative analyses. Instead it presents the results of a small qualitative effort meant to create a theoretical foundation for future research.

Methods
=======

This study used a participatory approach to explore \"recovery\" from the perspectives of addiction treatment professionals. It used inductive content analysis approaches to identify domains of recovery that could be modeled for further testing.

Setting
-------

The study was conducted at the Hanley Center, a private, 82-bed residential substance abuse treatment facility located in South Florida. The Hanley center serves a primarily white, private-pay clientele. The facility has separate treatment centers for men, women, and older adults. Comprehensive assessment and services are provided based on an eclectic model including medical, 12-step, cognitive/behavioral, and spiritual approaches delivered in individual, family, and small group modalities.

Participants
------------

There were eleven participants. Eight of these were managers of their respective disciplines at the Hanley Center, and three were researchers. The following disciplines or treatment perspectives were represented among the eight managers: medicine (physician and nurse); psychiatry; psychology; clinical therapy; social/emotional wellness; family/community; and spirituality. The multidisciplinary approach was used in order to obtain a comprehensive perspective on recovery. The researchers, who had expertise in addiction, research methodology, and neuroscience, lent their empirically-centered guidance to the process. Some of these participants were in recovery themselves. The participants included both men and women, all had a master\'s or doctorate degree in their discipline, and most had worked in the field of substance abuse for more than ten years.

Procedures
----------

The participants convened in group discussions at the Hanley Center over the period of one year to review literature, review the instruments used to collect data from Hanley clients, discuss practice observations and experiences, and derive findings in a prioritization process to define \"recovery\" and select measures to indicate the attainment of \"recovery.\" The researchers solicited and encouraged the managers/practitioners to inductively construct domains from the ground up to represent dimensions of \"recovery.\" Their responses were then merged with the existing literature to determine overlaps of concepts and reconcile differences in order to formulate a collective operational definition of \"recovery\" and select instruments that measure it.

Results
=======

The literature review and group discussion process led to the conclusion that a single industry-wide definition of \"recovery\" did not exist and that the multiple definitions that did exist were usually subjective and open for interpretation and often appeared more ideological than scientific. As a result of this process and conclusions, the participants inductively constructed seven domains that represent aspects, and are sensitive to status, of \"recovery\": physical; bio-marker; chemical dependency; psychological; psychiatric; family/social; and spiritual. This conceptual model is summarized in Table [1](#T1){ref-type="table"}. For each conceptual domain, potential operational measures are proposed. Some of these measures were already in use at the Hanley Center at the time of the group discussions, but others were not and were selected based on the literature review.

###### 

Conceptual Model of Substance Abuse Recovery

  Conceptual Domain     Potential Operational Measures
  --------------------- ----------------------------------------------------------------------------
  Physical              History and Physical
                        Urine Chemistry Panel
                        Brain Imaging
                        ASI Medical Subscale
                        
  Bio-Marker            Neuropeptides: Orexin, Oxytocin
                        Cortisol
                        
  Chemical Dependency   ASI Alcohol/Drug Use Subscales
                        Urine and Breath Screening
                        
  Psychological         MMSE or TONI-3
                        Shipley
                        
  Psychiatric           DSM-IV-TR Axis I
                        ASI Psychiatric Health Subscale
                        
  Family/Social         ASI: Employment/Self-Support, Family Relations, Illegal Activity Subscales
                        MMPI-2: Work Interference, Family Problems, Antisocial Practices Scales
                        
  Spiritual             Spirituality Self-Rating Scale
                        ASI-JCAHO Spirituality Scale

The model is holistic in that all the domains are hypothesized to be correlated with each other and all are considered important to recovery. However, it should be noted that not all domains will be relevant to all clients. For example, some addiction clients have co-occurring physical and psychological impairments wherein improvement may not be expected, and thus these domains would not be relevant elements of recovery for these individuals.

Definitions and Measurement of Domains
--------------------------------------

Each of the domains is defined below and the instruments that may be used to measure it are identified. All identified instruments have established reliability and validity.

### Physical Domain

Recovery is indicated in part by improvement in overall physical health. This may be measured by a history and physical examination, blood panels, brain imaging, and self-report. History, physical exam, and blood panels may be used to measure general signs, symptoms, and chemistries indicative of health and illness. Brain imaging using scans such as SPECT, PET, MRI, and functional MRI may be used to assess the effects of abused substances on the brain. Finally, the self-report medical health subscale of the Addiction Severity Index (ASI) \[[@B11]\] may be used to measure the physical domain.

### Bio-Marker Domain

Kraemer, Schultz, & Arndt \[[@B12]\] have defined a biomarker as a measurable characteristic of living tissues that indicates whether a specific event or process of medical interest has occurred, is occurring, or is likely to occur. Frank & Hargreaves \[[@B13]\] define a biomarker as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. The common theme captured in the definitions above is that biomarkers can provide readily accessible information regarding an individual\'s disease state.

We propose that relevant biomarkers for measuring recovery include neuropeptides and hormones. Specifically, we propose that the neuropeptides that may be used as indicators of substance use disorders and recovery are orexin (also known as hypocretin) and oxytocin. Neuropeptide transmitters are made exclusively in hypothalamic neurons and have extensive central nervous system projections. Harris & Aston-Jones \[[@B14]\] reveal a novel and important role for the orexin/hypocretin neuronal system in reward processing and addiction. The hypothalamus has been considered essential in motivational behaviors. Orexin is expressed in the lateral hypothalamus and has been implicated in the regulation of feeding behavior. Neurons expressing this neuropeptide have extensive projections to regions of the brain vital to behavioral responses to drugs of abuse, raising the possibility that these pathways are central when examining addiction \[[@B15],[@B16]\].

Some neuropeptides affect adaptive central nervous system processes related to opiate, ethanol, and cocaine addiction. Oxytocin, a neuropeptide synthesized in the brain and released at the posterior pituitary, is also released in the central nervous system. Oxytocin acts within the CNS to inhibit the development of tolerance to morphine. The behavioral tolerance to the effect of cocaine was inhibited by oxytocin while increasing behavioral sensitivity to cocaine. Tolerance to ethanol was also inhibited by oxytocin \[[@B17]\].

A hormone that may be measured to indicate recovery is cortisol. It has been determined that addiction patients appear to be biologically different from healthy subjects as indicated by greater cortisol blunting and other cortisol-related hormonal and psychological responses \[[@B18]\]. In fact, during early drug-quitting phases, cortisol levels were found to drop and be related to withdrawal distress and could be found to be associated with the attainment of abstinence \[[@B19],[@B20]\].

### Chemical Dependency Domain

This domain represents the extent to which the individual uses addictive chemicals. It may be measured using the alcohol and drug use subscales of the ASI, and urine and breath screening. A five panel urine quick screen may be administered to test for benzodiazepines, amphetamines, cocaine, THC and opiates. If the result is positive a quantitative test may be conducted to test for ethanol, amphetamine, barbiturate, benzodiazepines, cannabinoids, cocaine (metabolite), opiates, phencyclidine, methadone, propoxyphene, meperidine, and tramadol. A breathalyzer may be utilized for alcohol testing.

### Psychological Domain

Many persons suffering from addiction enter treatment in a significantly cognitively impaired state. Thus, improvement in gross cognitive functioning is indicative of recovery. Basic cognitive functioning may be measured with one of two instruments: the Folstein Mini-Mental State Examination (MMSE) \[[@B21]\] or the Test of Nonverbal Intelligence (TONI-3) \[[@B22]\]. The MMSE assesses orientation, registration, attention and calculation, recall, and language. Alternatively, the TONI-3 is administered to persons who have a cognitive impairment or who speak a language other than English. The test requires no reading, writing, speaking, or listening by the participant. Cognitive impairment in individuals with normal intelligence can be assessed using the Shipley Institute of Living Scale \[[@B23]\].

### Psychiatric Domain

This domain refers to the presence of a mental disorder. This may be measured by a diagnosis on Axis I of the *Diagnostic and Statistical Manual of Mental Disorders*\[[@B3]\]. Recovery would be indicated by a diagnosis of a disorder in remission. This domain may also be measured by the psychiatric health subscale of the ASI, which captures a somewhat different aspect of psychiatric functioning than does the DSM diagnosis.

### Family/Social Domain

This domain includes interaction with family and engagement with community. It may be measured using the employment/self support, family relations, and illegal activity subscales of the ASI, and the Work Interference, Family Problems, Antisocial Practices Scales of the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) \[[@B24]\].

### Spiritual Domain

This domain reflects the wide usage of Alcoholics Anonymous and other 12-step programs in the addiction rehabilitation community. It is defined as how an individual\'s way of life is reflected in thinking, speaking, and acting and the quality of one\'s relationships with oneself, others, and with a Higher Power. Spirituality may be measured with the Spirituality Self-Rating Scale \[[@B25]\] and the Spirituality Scale of the ASI-JCAHO Version \[[@B26]\].

Testing the Model
-----------------

The next step in this research process is to test the hypothesized conceptual model. Such a test would involve collecting data using all of the proposed instruments at intake into a treatment program and at predetermined time points thereafter. Following data collection, confirmatory factor analysis would be used to examine (1) the extent to which the proposed measurable indicators are representative of their respective conceptual domains, (2) the extent to which changes in the indicators occur over time; and (3) the extent to which the conceptual domains are correlated with each other initially and over time.

Confirmatory factor analysis would yield both an estimation of how well the model fit the data, and tests of specific hypotheses. For purpose (1) above, the null hypothesis is that each of the indicators within a domain are not correlated with each other. If so, this would demonstrate an absence of an underlying concept. However, if the null hypothesis were rejected, it would suggest that there is construct validity of the underlying concept or domain. For purpose (2), the null hypothesis would be that the indicators do not change over time as individuals proceed through the treatment and aftercare process. Rejection of the null hypothesis would suggest that these indicators are in fact indicative of recovery. For purpose (3), the null hypothesis is that the conceptual domains are not correlated; rejection would suggest convergent validity of the model. Additionally, this model could be further validated by correlating propensity scores derived from the model with clinicians\' independent ratings of the clients\' degree of recovery (i.e., known-groups validity).

As a result of this validation process, it is likely that the model would be refined. Some of the indicators may turn out not to adequately represent their respective domains (i.e., indicators not correlated with their domains), and some of the domains may turn out not to adequately represent recovery (i.e., domains not correlated with other domains). Thus, the model would likely be reduced through empirical testing. Individual components of the domains and biomarkers would need to be checked for sensitivity and specificity which would address effect size issues.

Discussion and Conclusions
==========================

This study has several limitations that should be noted. First, the participants represented a narrow selection of experts. Second, the study site, the Hanley Center, serves a fairly demographically homogeneous treatment population, which might bias the experts\' views. Third, some of the conceptual domains have more support in the treatment literature than others; for example, the biomarker domain primarily has research but not treatment support; however the aim of the proposed model is to test the treatment support for this domain.

This conceptual model represents an initial effort to build upon and expand upon traditional biopsychosocial models of addiction such as the syndrome model proposed by Schaffer et al. \[[@B27]\]. The syndrome model proposes a common etiology (e.g., distal antecedents such as neurobiology and proximal antecedents such as biopsychosocial events) that creates multiple expressions of the disease of addiction such as drug and alcohol misuse, gambling, smoking, psychiatric co-morbidities, social misconduct and biological malfunctioning. The syndrome model describes addiction. This paper proposes a potential model of recovery by incorporating elements of the syndrome model and reversing this process to build a model of recovery. The recovery model proposes that the reversal of addiction can be captured biologically through the measurement of neuroadaptations and hormonal shifts, and psychosocially with paper and pencil measures across the chemical dependency, psychiatric, psychological, family/social, and spiritual domains.

Additionally, the proposed model expands upon traditional biopsychosocial models by adding the bio-marker domain and the spiritual domain. In testing the bio-marker domain, neuropeptides and neuroadaptations may be examined to identify certain genes, DNA and core RNA for biological elements that are diagnostic of addiction, representative of recovery, and predictive of relapse. Additionally, cortisol may be examined to see if there are relationships between this hormone, stress, addiction, and recovery. Adding the spiritual domain incorporates the work of Galanter \[[@B8]\] who looks at addiction and recovery by examining how spiritual interventions can be used to support recovery efforts.

If the hypothesized conceptual model is supported by empirical data, it could provide a starting point for the development of a comprehensive, unifying perspective of recovery and its measurable indicators that could potentially be used to assess recovery in future outcome studies. This model would yield a conception of recovery as a continuum, rather than as a dichotomy (i.e., a person is either in recovery or not). In this model, the greater the improvement over time on a greater number of indicators, the greater the \"recovery\" would be considered to be. Additionally, a validated unifying model could provide a common metric across treatment programs that could allow for direct comparisons of effectiveness.
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